

Phenotypic detection of ESBL among *E. coli* and *Klebsiella pneumoniae* by CLSI guidelines in a Teaching Hospital MIMS, Mandya

Akshantha B. Sangannavar¹, Sahana Shetty N. S.^{2,*}, Sumangala B³

¹Consultant Microbiologist, ²Tutor, ³Professor & HOD, Dept. of Microbiology, ¹Gokula Metropolis Clinical Laboratories, MS Ramaiah Memorial Hospital, Bengaluru, Karnataka, ^{2,3}Mandya Institute of Medical Sciences, Mandya, Karnataka, India

***Corresponding Author:**

Email: sahanashettys@gmail.com

Abstract

Introduction: *Escherichia coli* and *Klebsiella pneumoniae* cause a wide range of infections. Multidrug-resistance strains carrying resistance genes have become a growing problem worldwide. The ESBLs have emerged distinctly, especially in *Escherichia coli* and *Klebsiella pneumoniae*.

Material and Methods: 250 non repetitive isolates of *E. coli* and *K. pneumoniae* were isolated from different clinical samples (pus, urine, sputum, blood) for the study. Each isolate was tested for production of ESBL by CLSI recommended PCT

Results: 133 *E. coli* and 117 *K. pneumoniae* were isolated where 65.2% of ESBL were detected.

Conclusion: All the clinical samples growing gram negative bacteria should be tested for ESBL, production. Considering the grave scenario of antibiotic resistance in our country, it is high time that all clinical laboratories start detecting these enzymes routinely and accurately.

Keywords: *Escherichia coli*, *Klebsiella pneumoniae*, ESBLs, CLSI.

Introduction

Antimicrobial resistance is a global health security emergency that is rising due to emergence of microorganisms that are no longer treatable because of their resistance to virtually all available antibiotic treatment options.

In 1990s, there was increasing appearance of extended spectrum β -Lactamase, presently metallo β -Lactamase prevalence is increasing. In current situation, multi-drug resistant bacteria have spread widely which is being seen through various mechanisms, of which resistance by production of enzymes are most common.

Emergence of antibiotic resistance in bacteria is a major concern in health care system. Bacteria have evolved different mechanisms of drug resistance. Resistance to β -Lactam antibiotics in gram negative bacilli is primarily mediated by β -Lactamases.

CDC estimates that in United States, more than two million people are sickened every year with antibiotic resistant infections, with at least 23,000 dying every year. ESBL (Extended Spectrum β -Lactamases) producing Enterobacteriaceae were first reported in 1983 from Germany & since then a steady increase of these strains has been reported worldwide.

Bush, Jacoby & Medeiros have classified β -Lactamases according to substrate profiles.

The prevalence of ESBLs in India has now reached epidemic proportions, ranging from 62% to 100% in *Escherichia coli* and *Klebsiella spp.* respectively as observed in the 10 Indian medical centre SENTRY study.

ESBL, AmpC β -Lactamases & Carbapenemases are major β -Lactamases released by pathogenic gram negative bacilli.

β -Lactamases are the commonest cause of bacterial resistance to β -Lactam antimicrobial agents. Their spread destroyed the utility of benzylpenicillin against *Staphylococci* and has hugely undermined that of ampicillin against *Enterobacteria* and *Haemophilus* and *Neisseria spp.* New enzymes and new modes of production of old enzymes now threaten the value of extended-spectrum cephalosporins against enterobacteria. Further β -Lactamases, some of which will become important in the future, are described in most issues of *Antimicrobial Agents and Chemotherapy* and in other journals.

The current β -Lactamase classifications have reached a high level of complexity, making them less accessible to clinicians, infection control professionals, hospital management and politicians. From the clinical perspective, a revised comprehensible nomenclature scheme is therefore needed. The term extended-spectrum β -lactamases (ESBLs) has reached a broader audience over time, but is currently restricted to functional class 2b/molecular class A, clavulanic acid inhibited enzymes with activity against extended-spectrum cephalosporins. The proposed new classification expands the definition of ESBL to other clinically important acquired β -Lactamases with activity against extended-spectrum cephalosporins and/or carbapenems. The classical class-A ESBLs have been designated ESBLA in this classification, whereas plasmid-mediated AmpC and OXA-ESBLs are classed as miscellaneous ESBLs (ESBLM). Lastly, the carbapenemases have been designated ESBLCARBA, ESBLs with hydrolytic activity against carbapenems. We believe that this simplified classification may encourage new groups of healthcare professionals to

engage in the effort to prevent the spread of acquired β -Lactamases.

Aims and Objectives

1. Phenotypic detection of ESBL enzyme producing *E.coli* & *K pneumoniae*.
2. To know the prevalence of β -Lactamase producing *E.coli* & *Klebsiella pneumoniae*.

Material and Methods

All samples were routinely cultured on MacConkey and blood agar plates. These plates were routinely incubated at 37°C aerobically and after overnight incubation, they were checked for bacterial growth. The organisms were identified by their colony morphology, staining characters, pigment production, motility and other relevant biochemical tests as per standard laboratory methods of identification.

Isolation and identification of organisms

Suspected Gram negative organisms were identified by colony characteristics, motility, oxidase reaction, citrate utilization, indole and gas production and sugar fermentation reactions. Triple sugar iron agar was used for H₂S production, sugar fermentation.

Maintenance and preservation of culture strains

Organisms grown in appropriate media for 18 hours were preserved in a nutrient agar slant at 2-8°C in a refrigerator.

Samples (Sputum, pus, urine, blood, ear discharge) received for culture and sensitivity testing to microbiology laboratory of MIMS will be processed as following.

The samples were plated onto blood agar and Macconkey agar. The Macconkey agar plate showing lactose fermenting (pink) colonies were confirmed to be *E coli* and *Klebsiella pneumoniae* by series of biochemical tests.

Clinical isolates of *E. coli* & *Klebsiella pneumoniae* identified as per above mentioned procedure was selected for the study.

Quality Control (QC) organisms used for the study:

E. coli ATCC 25922

Klebsiella pneumoniae ATCC 700603

Modified Kirby-Bauer sensitivity testing method was used for this purpose. Muller Hinton agar media was used, which has PH 7.2-7.4. Media was transfer in to 90 mm diameter sterile Petri dishes to a depth of 4 (four) mm. The surface was lightly and uniformly inoculated by cotton swab in three directions rotating the plate approximately 60°, to ensure even distribution. Prior to inoculation, the swab stick was dipped into bacterial suspension having visually equivalent turbidity to 0.5McFarland standards. The swab stick was then took out and squeezed on the wall of the test tube to discard extra suspension. Inoculated plates were incubated at 37 °C for 24 hours. On the next day, plates were read by taking measurement of zone of inhibition. Testing for ESBL production

a. Screening test

Following antibiotic disks will be placed on MHA after performing a lawn culture of the test organism, incubated at 35°C for 24 hours. The zone diameter is measured after 24 hours.

Antibiotic	Zone size for possible ESBL producing strains
Aztreonam(30µg)	≤27mm
Cefotaxime(30µg)	≤27mm
Cefpodoxime(30µg)	≤22mm
Ceftazidime(30µg)	≤22mm
Ceftriaxone(30µg)	≤25mm

Screen positive isolates are further tested for confirmation of ESBL production

b. CLSI phenotypic confirmatory test

By disk diffusion method: After performing a lawn culture of the test organism, a ≥5mm increase in zone diameter for cefotaxime(30µg)& ceftazidime(30µg) tested in combination with clavulanic acid(CA) versus its zone when tested alone confirms an ESBL producing organism.

Results

Table 1: Distribution of *E. coli* and *K. pneumoniae* isolates in males and females

Organism	Gender		Total
	Female	Male	
<i>E. coli</i>	72(54.1%)	61(45.9%)	133(53.2%)
<i>K. pneumoniae</i>	31(26.5%)	86(73.5%)	117(46.8%)
Total	103(41.2%)	147(58.8%)	250(100%)

Table 2: Distribution of *E. coli* and *K. pneumoniae* isolates in males and females

Organism	Gender		Total
	Female	Male	
<i>E. coli</i>	72(54.1%)	61(45.9%)	133(53.2%)
<i>K. pneumoniae</i>	31(26.5%)	86(73.5%)	117(46.8%)
Total	103(41.2%)	147(58.8%)	250(100%)

Above table shows distribution of isolates in males and females, where *E. coli* have been isolated 0 with female preponderance. 117 *K. pneumoniae* are isolated with male preponderance.




Fig. 1: Shows Sex wise Distribution of *E. coli* and *K. pneumoniae* isolates

Table 3: Age distribution of patients with *E. coli* and *K. pneumoniae* isolates

Age in years	Organism		Total
	<i>E. coli</i>	<i>K. pneumoniae</i>	
1-30 days	0	5(4.3%)	5(2%)
1-12 months	1(0.8%)	1(0.9%)	2(0.8%)
1-2 years	2(1.5%)	4(3.3%)	6(2.4%)
3-5 years	5(3.7%)	2(1.7%)	7(2.8%)
6-10 years	3(2.3%)	2(1.7%)	5(2%)
11-15 years	4(3%)	0	4(1.6%)
16-20 years	10(7.5%)	5(4.3%)	15(6%)
>20 years	108(81.2%)	98(83.8%)	206(82.4%)
Total	133(100%)	117(100%)	250(100%)

Above table shows age distribution and isolate distribution in patients studied, where majority of samples 206(82.4%) were received from patients aged more than 20yrs.

17 (12.8%) samples were in age between 11-25 years from urine of females with UTI.

Only *K. pneumoniae* was isolated from neonates (blood culture and sensitivity).




Fig. 2: Age distribution of patients with *E. coli* and *K. pneumoniae* isolates

Table 4: Sample wise distribution of isolates

Organism	PUS	Sputum	Urine	Blood	Total
<i>E. coli</i>	50(37.6%)	13(9.8%)	70(52.6%)	0	133(100%)
<i>K. pneumoniae</i>	46(39.3%)	50(42.7%)	15(12.8%)	6(5.2%)	117(100%)
Total	96(38.4%)	63(25.2%)	85(34%)	6(2.4%)	250(100%)

Out of 250 samples studied, majority of samples 96(38.4%) were from pus, 85(34%) were from urine and 63(25.2%) from sputum. *E.coli* was isolated 133 out of 250 samples, 70(52.6%) from urine samples majority were young females suffering from UTI.

K. pneumoniae was isolated from 117 out of 250 samples, 50(42.7%) from sputum samples, 46(39.3%) from pus samples and 15(12.8%) from urine samples.

From blood samples only *K. pneumoniae* was isolated in 6 cases.




Fig. 3: Sample wise distribution of isolates

Table 5: Distribution of isolates showing ESBL positive by screening and confirmatory test

Organism	ESBL by Screening		ESBL Confirmed	
	Negative	Positive	Negative	Positive
<i>E. coli</i> (n=133)	25(18.8%)	108(81.2%)	45(33.8%)	88(66.2%)
<i>K. pneumoniae</i> (n=117)	29(24.8%)	88(75.2%)	42(35.9%)	75(64.1%)
Total(n=250)	54(21.6%)	196(78.4%)	87(34.8%)	163(65.2%)

Above table shows detection of ESBL. Out of 133 *E. coli* isolated, 108(81.2%) screened positive and 88(66.2%) were confirmed ESBL by CLSI recommended method and out of 117 *K. pneumoniae* isolated, 88(75.2%) screened positive and 75(64.1%) confirmed positive for ESBL.

Discussion

Table 1 shows gender distribution of isolates where female preponderance of *E. coli* can be attributed to UTI caused by the organism.

In the present study, a total of 250 strains are studied, of which 133 are *E. coli* and 117 are *K. pneumoniae*.

Most of the isolates are from sample collected from patients aged over 20 years as shown in table 1, which can be attributed to their environmental exposure and outdoor activity.

Of the manual ESBL confirmation methods, disk augmentation displayed the overall highest positivity rate, whereas E test detected ESBL production in only 2/26 isolates and yielded a high number of non-determinable results.

Rastogi V, et al. and Garrec H, et al. reported higher rates (100% and 93% respectively) of incidence than our study.

While study by Rodrigues C, et al., Babypadmini S, et al. and Bhattacharjee A, et al. reported the rate to be 40% to 62.5% with the CLSI recommended

Phenotypic confirmation method, which is lower than our study rates.

It is assumed that this high rate of ESBLs by phenotypic method, may be due to mutation of first two parent gene TEM-1, SHV-1 and newer most prevalent gene CTX-M in the world. CTX-M gene now the most common in *E.coli* in community and it may be due to over use of ceftriaxone or due to fecal carriage and transfer gene by horizontal transmission.

Isolates that test positive with screening test but negative on confirmatory test should be looked for CMY-2 and FOX-5 Amp C genes.

In India, high prevalence of ESBL producing *Klebsiella* strains has been reported by various groups. Reported frequency of ESBL producing *Klebsiella* spp. from India ranged between 6 and 87 per cent.

Conclusion

ESBLs producing Gram-negative bacteria are an increasing public health problem worldwide because of their resistance to β -lactam antibiotics. ESBL, gene are typically carried on transferable plasmids or are part of the bacterial chromosome. This enzyme which have been detected primarily in *E. coli* and *K. pneumoniae* but were also found in other Gram negative bacteria, including non-fermenters and members of the family Enterobacteriaceae.

Because resistance to broad spectrum antibiotic β lactams is linked to various molecular mechanisms

involving a wide variety of enzymes, detection has become diagnostic challenge in clinical laboratories.

In our study, since, detection of ESBL is over 80%, this study indicates that routine ESBL detection should be made imperative and empirical use of third generation cephalosporins must be discouraged.

In most cases, the standard disk diffusion tests are effective. ESBL detection in routine laboratories are done by disk diffusion methods. Considering the grave scenario of antibiotic resistance in our country, it is high time that all clinical laboratories start detecting these enzymes routinely and accurately.

References

1. Paterson DL, Bonomo RA. Extended-spectrum β -Lactamases: A clinical update. *Clin Microbiol Rev* 2005;18:657-86.
2. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β -lactamases and its correlation with molecular structure. *Antimicrob Agents Chemother* 1995;39:1211-33.
3. Mathai D, Manoharan A, Vasanthan G. Epidemiology and Implications of ESBL. *Crit Care Update* 2009;14:152-62.
4. Thomson KS. Extended-Spectrum- β -Lactamase, AmpC, and Carbapenemase Issues. *J Clin Microbiol* 2010;48(4):1019-25.
5. Nathisuwan S, Burgess DS, Lewis JS. ESBLs: Epidemiology, Detection and Treatment Pharmacotherapy 2001;21(8):920-28.
6. Hoşoğlu S, Gündeş S, Kolaylı F, Karadenizli A, Demirdağ K, M Günaydın, et al. Extended-spectrum beta lactamases in ceftazidime resistant *Escherichia coli* and *Klebsiella pneumoniae* isolates in Turkish hospitals. *Ind J Med Microbiol* 2007;25(4):346-50.
7. Davies J, Davies D. Origins and Evolution of Antibiotic Resistance. *Microbiol Mol Biol Rev* 2010;74:3417-33.
8. Greenwood. Antimicrobial Drugs. Chronicle of a Twentieth Century Medical Triumph; 1960.
9. Abraham EP, Newton GGF. The structure of cephalosporin C. *Biochem J* 1961;79:377-93.
10. Brooks G, Butel S, Morse S. Enteric Gram-negative rods (Enterobacteriaceae). In: Jawetz, Melnick & Adelberg's Medical Microbiology. 24thed. New York: McGraw-Hill USA; 2007:229-243.
11. Tortora GJ, Berdell R, Funke and Christine L. Comparison of the structure and composition of Gram-positive and gram negative cell walls. Pearson Education; 1989. Figure 4-11; p.83.
12. Ambler RP. The structure of β -lactamases. *Philos Trans R Soc Lond B Biol Sci* 1980;289:321-31.
13. Spratt BG. Distinct penicillin binding proteins involved in the division, elongation, and shape of *Escherichia coli* K12. *Proc Nat Acad Sci USA* 1975;72(8):2999.
14. Spratt BG, Boyd A, Stoker NG. Defective and plaque-forming lambda transducing bacteriophage carrying penicillin-binding protein-cell shape genes: genetic and physical mapping and identification of gene products from the lip-dacA-rodA-pbpA-1 *J Bacteriol* 1980;143:569-81.
15. Smith BJK. Construction of a mutant of *Escherichia coli* that has deletions of both the penicillin-binding protein 5 and 6 genes. *J Gen Microbiol* 1985;131(8):2115-8.
16. Spratt BG, Pardee AB. Penicillin-binding proteins and cell shape in *E. coli*. *Nature* 1975;254(5500):516-17.
17. Tipper DJ. Mode of Action of β -Lactam Antibiotics. *Clin Infect Dis* 1979;1(1):39-53.
18. Bradford PA. Extended-Spectrum β -Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat. *Clin Microbiol Rev* 2001;14(4):933-51.
19. Rupp ME, Fey PD. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. *Drugs* 2003;63(4):353-65.
20. Rodriguez GJA, Jones RN. Antimicrobial resistance in gram-negative isolates from European intensive care units: data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme. *J Chemother* 2002;14:25-32.
21. Manobalan K, Menezes GA, Harish BN. Study of ESBLs and AmpC beta Lactamases in *E.coli*, *K. spp.* and *Enterobacter spp.* in a tertiary care hospital. *Research Journal of Pharmaceutical, Biological and Chemical Sciences* (Impact Factor: 0.35). 11/2014;5(6):184-89.
22. Swarna SR, Srimathi NN, RadhaMadhavan & Gomathi S. Correspondence Performance of extended spectrum beta lactamases (ESBL) screening agar in various clinical specimens. *Ind J Med Res* 2015;141(4):481-82.